Hi [[ session.user.profile.firstName ]]

Qualidade e Acreditação em Laboratórios-Uma Abordagem da Influência da Vidraria

Jeronimo Figueiredo, Business Operations - Latin America, Engenheiro Químico, Corning Life Sciences
Recorded Jun 2 2020 60 mins
Your place is confirmed,
we'll send you email reminders
Presented by
Jeronimo Figueiredo
Presentation preview: Qualidade e Acreditação em Laboratórios-Uma Abordagem da Influência da Vidraria

Network with like-minded attendees

  • [[ session.user.profile.displayName ]]
    Add a photo
    • [[ session.user.profile.displayName ]]
    • [[ session.user.profile.jobTitle ]]
    • [[ session.user.profile.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(session.user.profile) ]]
  • [[ card.displayName ]]
    • [[ card.displayName ]]
    • [[ card.jobTitle ]]
    • [[ card.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(card) ]]
  • Channel
  • Channel profile
  • Organogenesis to Oncogenesis - POSTPONED Mar 23 2021 3:00 pm UTC 45 mins
    Dr. Joseph Regan
    THIS WEBINAR IS POSTPONED UNTIL FURTHER NOTICE

    Organogenesis to Oncogenesis: Modeling Development and Cancer with Organoids
    Organoid cell culture allows mammalian stem cells to differentiate and self-organize into three-dimensional organ-like tissues that reflect the key structural and functional properties of the organs from which they are derived. In addition, organoids can be grown from patient-derived healthy and tumor tissue to provide genetically and phenotypically stable personalized preclinical models. Organoid technologies therefore provide a unique in vitro system in which to study human organ development and cancer.

    In this webinar, Dr. Regan will discuss the use of organoid technologies to study organogenesis and cell fate determination in the postnatal mammary gland. In addition, the use of patient-derived organoids (PDOs) to elucidate the molecular mechanisms that regulate oncogenesis and contribute to tumor heterogeneity in colon cancer will be discussed.

    Presenter:
    Dr. Joseph Regan graduated from The Institute of Cancer Research (University of London, UK) with a Ph.D. in Cell Biology and received postdoctoral training at the Breast Cancer Now Research Centre (London, UK) and the Max Planck Institute for Molecular Genetics (Berlin, Germany). Dr. Regan subsequently worked as a Research Scientist with Bayer AG and the Charité Medical University (Berlin, Germany), where he uses patient-derived organoid models to study cancer stem cells and tumor heterogeneity in colon cancer.
  • Calidad y Acreditación en Laboratorios Un Abordaje de la Influencia de Vidrios Jul 22 2020 7:00 pm UTC 60 mins
    Jerónimo Figueiredo
    Calidad y Acreditación en Laboratorios - Un Abordaje de la Influencia de la Vidriería para Laboratorios
    Jerónimo Figueiredo - Business Operations Manager
  • がんオルガノイドを用いた抗がん剤の評価 Jul 22 2020 5:00 am UTC 90 mins
    公立大学法人 福島県立医科大学 ふくしま国際医療科学センター  医療-産業トランスレーショナルリサーチセンター セルファクトリー部門 教授 高木 基樹 先生
    がん組織より樹立した長期培養が可能な「がんオルガノイド(F-PDO®)」と「がん細胞株」とのゲノム、遺伝子発現、形態等の違い、がんオルガノイドの培養やアッセイ系構築の難しさ、がん細胞株(平面培養)との抗がん剤の感受性の違いなどについて紹介致します。

    <セミナーのポイント>
    ① がんオルガノイドの樹立と培養
    ② がんオルガノイドの特徴
    ③ がんオルガノイドを用いたアッセイ系構築のポイント
    ④ がんオルガノイドとがん細胞株の抗がん剤感受性の相違
  • A Guide to Cryogenically Storing Animal Cell Cultures Jul 16 2020 4:00 pm UTC 60 mins
    Kyung-A (Katie) Song, Ph.D.
    Maintaining healthy, growing cell cultures is a demanding task made more difficult by the everpresent risk of their loss through accidents or contamination. In addition, actively growing cell cultures are not static but, like all populations of microorganisms, subject to age-related or environmentally-induced changes which can result in their ongoing evolution and potential loss.

    This webinar will cover:
    - The advantages of freezing cell cultures
    - General events during cell freezing
    - Practical aspects of cell freezing

    Speaker Bio:
    Dr. Kyung-A Song graduated from Sungkyunkwan University with a Ph.D. in molecular biology and cancer immunology. She completed her postdoctoral fellowship in pharmaceutical research and drug discovery at Virginia Commonwealth University. She has extensive experience in a variety of cell culture techniques including isolation and culture of primary patient cells. She has worked with xenograft models and many cancer cell lines, and she has expertise in in vitro cell based functional assays and in vivo experiments. She is currently a Scientific Support Specialist for Corning Life Sciences where she answers customer inquiries about all products in the extensive Corning Life Sciences product portfolio.
  • Organoids Master Class: Brain Organoids & Their Application in Disease Modeling Jul 14 2020 6:00 pm UTC 60 mins
    Richa Singhania, Ph.D., Director, Brain Organoid Core at Weill Cornell Medicine
    Join us for the next webinar in our Organoids Master Class Series with our guest speaker, Richa Singhania, Ph.D., Director, Brain Organoid Core at Weill Cornell Medicine. In the presentation she will cover:
    •An overview and generation of cerebral organoids
    •Advances in brain organoid technologies
    •Modeling neurological disorders, including brain tumors and understanding neurological effects of viruses, including SARS-CoV-2

    Speaker Bio:
    Richa is passionate about bringing precision medicine to the masses and make preclinical research successful to ultimately improve the lives of people affected by cancer. Richa has over 10 years of experience in translational cancer research, and her latest research is based on using stem cells and organoids for cancer modeling and drug discovery. Richa obtained a Masters in Biotechnology and PhD in Molecular Biology from University of Queensland, Australia. Thereafter, she completed postdoctoral fellowships at academic institutions in USA and UK. Currently, she is spearheading the Starr Foundation Cerebral Organoid Translational Core at Weill Cornell Medicine, New York which integrates latest advances in organoid and automation technologies to create personalized solutions for brain cancer patients.
  • The Race for More Cells - Progress and Challenges in Maximizing Cell Densities Recorded: Jun 30 2020 59 mins
    Amit K Sharma
    Scientific progress in the cell and gene therapy field will accelerate clinical cell therapy programs in the coming years. As cell therapy trials advance from pre-clinical research to late-stage trials, cell culture platforms will need to meet increasing demands for cell yield and high cell densities while maintaining product quality and minimizing operating costs. To meet demand, traditional production methods that rely on planar cell culture vessels will require improvements in scale-out output, which can be quite tedious as a manual process.

    The challenge, then, becomes establishing an adherent culture platform that can effectively scale from relatively small needs of pre-clinical studies through Phase I/II trials and into Phase III. As a result, the ability to scale-out will ease the transition from process development to manufacturing.

    This webinar provides potential solutions that may be considered to improve cell density and productivity in adherent cell culture in the areas of vaccines and viral vector production. It will also highlight the perfusion-based Corning® CellCube® system as a flexible, modular method for maximizing cell and high titer retroviral vector yields.
  • Introducción al cultivo celular 3D Recorded: Jun 25 2020 57 mins
    Alfredo Javier Hernandez
    Alfredo Javier Hernandez- Account Manager Corning LifeSciences, maestro en ciencias especializado en biología celular
  • Rescheduled: Role of HUB Organoids in Treating Infectious Diseases Recorded: Jun 25 2020 45 mins
    Dr. Sylvia F. Boj, Chief Research Officer, Hubrecht Organoid Technology
    Key to the development of the Organoid Technology was the discovery of LGR5+ intestinal adult stem cells by the Clevers lab. When provided with the appropriate growth factors, HUB Organoids proved to be both genetically and phenotypically stable during prolonged periods of cell culture and are amenable to all standard experimental manipulations, including middle through-put drug screen.

    Because HUB Organoids can be generated from normal/healthy tissue and they maintain individual and tissue-specific characteristics, they have the potential to model viral infection diseases with relevant clinical implications such Hepatitis B (HBV), Respiratory Syncytial (RSV) and more recently Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV2). At the same time, HUB Organoids can be used as a relevant patient model in (pre-)clinical phases to test effective drug treatments for infectious diseases, from which a relevant patient model was not available before.

    About the Presenter:
    Sylvia F Boj received her PhD in 2006 at the University of Barcelona, Spain for her work at IDIBAPS on functional genetic analysis for deciphering the transcriptional role of MODY genes in pancreatic beta cells.

    With a long term EMBO fellowship, she subsequently joined the Hubrecht Institute (Utrecht, the Netherlands) as a postdoctoral fellow. In the laboratory of Prof. Hans Clevers she first studied the role of TCF7L2 regulating metabolism. Then, she established an in vitro organoid model for human pancreatic cancers. In 2014, she moved to Hubrecht Organoid Technology (Utrecht, the Netherlands) as a group leader for Cystic Fibrosis and Cancer programs. In 2016, she was appointed as Scientific Director of HUB, with the ultimate goal of transferring scientific advances of the Organoid Technology to the development of new drugs, by interacting with pharmaceutical companies, and developing clinical trials to validate the predictive value of the Organoids for the response of patients.
  • ヒトiPS細胞由来高品質心筋細胞の大量作製法の開発と心臓再生医療への応用 Recorded: Jun 23 2020 70 mins
    慶應義塾大学循環器内科 臓器再生医学寄附講座 特任講師 遠山周吾先生
    ヒトiPS細胞から作製した心筋細胞を用いた再生医療を実現化するにはさまざまな課題を克服する必要があります。本セミナーではその課題を克服するためのアプローチを紹介します。

    ポイント:
    ・ヒトiPS細胞を用いた再生医療における課題について 
    ・ヒトiPS細胞から心筋細胞を大量に作製・回収する方法について
    ・ヒトiPS細胞由来の分化細胞集団から心筋細胞のみを選別する方法について 
    ・ヒトiPS細胞由来の心筋スフェロイドを大量に作製する方法について
  • Identifying and Correcting Common Cell Growth Problems Recorded: Jun 16 2020 48 mins
    Dr. Ann E. Rossi
    Introduction - Common cell growth problems and fundamentals of healthy cell cultures: 1:42 - 13:17
    Problems related to technique: 13:18 - 19:44
    Problems related to media: 19:45 - 26:39
    Problems related to cell culture incubators: 26:40 - 33:43
    Guide for troubleshooting - general tips and tricks: 33:44 - 38:08
    Q&A Session: 38:08 - 47:54

    Cell Culture is a powerful research tool in the life sciences. However, the dynamic nature of living cells can make cell culture a difficult tool to work with in the laboratory, even for the most experience hands. As one of the major suppliers of vessels, media, and sera used in cell culture, Corning Life Sciences often receives calls from anxious customers who are experiencing growth or attachment problems with their cell lines to determine what is responsible for the erratic behavior or loss of their cultures. Identifying the underlying causes of erratic cell behavior, unexplained experimental results, or loss of cultures is often a difficult, time-consuming task. This webinar will help identify and solve common cell culture problems can be traced to the three common problem areas of technique, incubators, and media.

    Dr. Ann E. Rossi graduated from the University of Rochester School of Medicine and Dentistry with a Ph.D. in Pharmacology and received postdoctoral training at the University of Chicago. Ann began her career with Corning Life Sciences as the Applications Lab Manager where she utilized her strong academic and industry research experience to direct the activities of the Applications Laboratory. Currently, Dr. Rossi is the Senior Bioprocess Applications Scientist, functioning as the technical lead for generating applications in support of Corning Life Sciences’ Bioprocess and Cell/Gene Therapy portfolios including CellCube and HYPERStack platforms.
  • An optimal Environment Across All Stages of Cell Culture [ENG. VERSION] Recorded: Jun 11 2020 29 mins
    Dr. Lindsey Parker
    The Life Sciences Rendez-vous : Bioprocess, Media and Sera - PART 3/3.
    Attend our new compact webinars series (30min) in your local language.
    See Part 1, Part 2 and other languages on our webinar page.

    Media and Sera are crucial components in cell culture – providing nutrition such as inorganic salts, amino acids and vitamins, or growth factors to your cells – and optimal products should be carefully selected.
    This webinar presents an overview of Corning’s media and sera portfolio, and how these may enhance both production and research in bioprocess applications.
    Corning’s media and serum offering includes:
    •Many different formulations of standard media to meet specific applications
    •Serum- free and specialty media
    •Standard and premium origin sera
    •A choice of specialty sera and treatments for optimal cell culture and assay performance
    Join this webinar for an overview of how our media and sera can fit into your workflow.

    About presenters:

    Dr. Lindsey Parker
    Lindsey completed her Ph.D. in Tissue Engineering and Regenerative Medicine at the University of Leeds (UK), validating a bioreactor for the application of mechanical stimuli to MSC. She subsequently joined UCL as an industrial KTP associate, leading clinical research in umbilical cord- derived MSC scale-up in collaboration with a tissue bank. Lindsey is currently a Bioprocess Sales Specialist at Corning, providing specialist support in bioprocess ranges, such as advising on product selection, custom products, and providing training.
  • An optimal Environment Across All Stages of Cell Culture [FR. VERSION] Recorded: Jun 11 2020 33 mins
    Dr. Sonia Meconi
    The Life Sciences Rendez-vous : Bioprocess, Media and Sera - PART 3/3.
    Attend our new compact webinars series (30min) in your local language.
    See Part 1, Part 2 and other languages on our webinar page.

    Media and Sera are crucial components in cell culture – providing nutrition such as inorganic salts, amino acids and vitamins, or growth factors to your cells – and optimal products should be carefully selected.
    This webinar presents an overview of Corning’s media and sera portfolio, and how these may enhance both production and research in bioprocess applications.
    Corning’s media and serum offering includes:
    •Many different formulations of standard media to meet specific applications
    •Serum- free and specialty media
    •Standard and premium origin sera
    •A choice of specialty sera and treatments for optimal cell culture and assay performance
    Join this webinar for an overview of how our media and sera can fit into your workflow.

    About presenters:

    Dr. Sonia Meconi
    Sonia’s scientific background covers different fields such as biochemistry, cell biology, and immunology where she obtained a Ph.D., specifically in human infectious diseases working on a daily basis in a biologic level 3 lab. After a post-doctoral fellow and lecturer experience, she took over the head of the R&D and production teams in a small biotech which developed human serological diagnosis assays for infectious and autoimmune diseases. She oversaw pathogens (bacteria and virus) expansion supervision for protein microarray tests. Then, she joined an international company as an Application Specialist for cell culture and purification, creating new cell culture media dedicated to vaccines and cell therapy markets. Now, she joined Corning as Bioprocess Specialist working for different suppliers for the biopharmaceutical industry.
  • An optimal Environment Across All Stages of Cell Culture [GER. VERSION] Recorded: Jun 10 2020 25 mins
    Dr. Franziska Wienholz
    The Life Sciences Rendez-vous : Bioprocess, Media and Sera - PART 3/3.
    Attend our new compact webinars series (30min) in your local language.
    See Part 1, Part 2 and other languages on our webinar page.

    Media and Sera are crucial components in cell culture – providing nutrition such as inorganic salts, amino acids and vitamins, or growth factors to your cells – and optimal products should be carefully selected.
    This webinar presents an overview of Corning’s media and sera portfolio, and how these may enhance both production and research in bioprocess applications.
    Corning’s media and serum offering includes:
    •Many different formulations of standard media to meet specific applications
    •Serum- free and specialty media
    •Standard and premium origin sera
    •A choice of specialty sera and treatments for optimal cell culture and assay performance
    Join this webinar for an overview of how our media and sera can fit into your workflow.

    About presenters:

    Dr. Franziska Wienholz
    Franziska completed her Ph.D. in Molecular Genetics at the Erasmus MC,The Netherlands, focusing on studying DNA repair and related diseases. During her research, she acquired extensive knowledge on cell culture and patient-derived materials, molecular techniques, and genome editing.
  • Introdução ao Cultivo de Células 3D Recorded: Jun 9 2020 53 mins
    Luiz Gustavo Mendes
    Luiz Gustavo Mendes, MSc Field Applications Scientist Corning LifeSciences
  • The Use of Multi-species Organoids Recorded: Jun 9 2020 47 mins
    Dr. Valentina Ubertini
    Title: The Use of Multi-species Organoids as a Pre-clinical Screen to Assess Gastrointestinal Toxicity

    The small intestinal organoid model (Sato, et al. 2009) incorporates many of the physiologically relevant features of the in vivo intestinal epithelium, including the presence of all the differentiated cell types and the regenerative progenitor cells. We have validated the organoid model as a screening tool to predict GI toxicity (a common and often severe dose-limiting side effect of chemotherapy) and subsequent mucosal regeneration in four species: mouse, rat, canine and human. Using minimal amounts of drug candidates, these assays are much quicker to perform than in vivo models but have been shown to be highly predictive of the in vivo response. Readouts can include viability and proliferation, but also can include more detailed mechanistic information via gene expression profiling (Next Generation Sequencing), immunohistochemistry, in situ hybridisation (RNAscope), and cytokine profiling.

    Speaker Bio:
    Dr Valentina Ubertini completed her Ph.D. researching the relationship between p53 and the anti-inflammatory cytokine sIL-1Ra at Regina Elena National Cancer Institute, Rome, Italy. She then moved to the Cancer Research UK Manchester Institute to investigate the regulation of inflammatory genes modulating the prostate cancer microenvironment. This experience, using a variety of 3D cell culture models (organoids, spheroids) of both primary cells and cell lines, led her to Epistem, Manchester, UK (a company with a history of providing a range of high quality pre-clinical gastrointestinal research services), to lead a team developing a range of intestinal organoid assays as predictive toxicity screens for novel therapeutics.
  • Producción de Vacunas: Soluciones Corning en Bioproceso Recorded: Jun 4 2020 53 mins
    Alfredo Javier Hernandez
    Alfredo Javier Hernandez- Account Manger Corning LifeSciences, maestro en ciencias especializado en biología celular
  • Bioprocess Suspension Solutions - Suspension Workflow [ENG. VERSION] Recorded: Jun 4 2020 19 mins
    Constanza Curotto
    The Life Sciences Rendez-vous : Bioprocess, Suspension - PART 2/3.
    Attend our new compact webinars series (30min) in your local language.
    See Part 1, Part 3 and other languages on our webinar page.

    Careful vessel selection at all scales enhances space efficacy, reducing cost and labor hours. Suspension processes play a key role in the biopharmaceuticals market, where suspension cell systems are used to produce antibodies and recombinant proteins. This webinar will provide an overview of Corning's suspension culture portfolio, relevant to both R&D and production scenarios, supported by experimental data from our global applications team.

    About Presenter:

    Constanza Curotto
    After graduating from Biochemistry in the University of Santiago (Chile), Constanza pursued directly a career in the Chilean Vaccine R&D industry, developing as a bioprocess scientist for both bacterial and viral vaccines in the field of animal health, being in charge of scale-up, and tech transfer with manufacturing plants. She furthered developed her career in Belgium as a bioprocess scientist, this time in the field of recombinant protein production, pursuing protocol optimization and scale-up experiments with suspension mammalian cell lines. Constanza is currently a field applications scientist in Corning for the EMEA region, providing customers with in-depth technical support, presenting seminars and trainings, and assisting customers in experimental set-up and troubleshooting.
  • Bioprocess Suspension Solutions - Suspension Workflow [FR. VERSION] Recorded: Jun 4 2020 29 mins
    Dr. Sonia Meconi
    The Life Sciences Rendez-vous : Bioprocess, Suspension - PART 2/3.
    Attend our new compact webinars series (30min) in your local language.
    See Part 1, Part 3 and other languages on our webinar page.

    Careful vessel selection at all scales enhances space efficacy, reducing cost and labor hours. Suspension processes play a key role in the biopharmaceuticals market, where suspension cell systems are used to produce antibodies and recombinant proteins. This webinar will provide an overview of Corning's suspension culture portfolio, relevant to both R&D and production scenarios, supported by experimental data from our global applications team.

    About Presenter:

    Dr. Sonia Meconi
    Sonia’s scientific background covers different fields such as biochemistry, cell biology, and immunology where she obtained a Ph.D., specifically in human infectious diseases working on a daily basis in a biologic level 3 lab. After a post-doctoral fellow and lecturer experience, she took over the head of the R&D and production teams in a small biotech which developed human serological diagnosis assays for infectious and autoimmune diseases. She oversaw pathogens (bacteria and virus) expansion supervision for protein microarray tests. Then, she joined an international company as an Application Specialist for cell culture and purification, creating new cell culture media dedicated to vaccines and cell therapy markets. Now, she joined Corning as Bioprocess Specialist working for different suppliers for the biopharmaceutical industry.
  • Bioprocess Suspension Solutions - Suspension Workflow [GER. VERSION] Recorded: Jun 4 2020 28 mins
    Dr. Franziska Wienholz
    The Life Sciences Rendez-vous : Bioprocess, Suspension - PART 2/3.
    Attend our new compact webinars series (30min) in your local language.
    See Part 1, Part 3 and other languages on our webinar page.

    Careful vessel selection at all scales enhances space efficacy, reducing cost and labor hours. Suspension processes play a key role in the biopharmaceuticals market, where suspension cell systems are used to produce antibodies and recombinant proteins. This webinar will provide an overview of Corning's suspension culture portfolio, relevant to both R&D and production scenarios, supported by experimental data from our global applications team.

    About Presenter:

    Dr. Franziska Wienholz
    Franziska completed her Ph.D. in Molecular Genetics at the Erasmus MC,The Netherlands, focusing on studying DNA repair and related diseases. During her research, she acquired extensive knowledge on cell culture and patient-derived materials, molecular techniques, and genome editing.
  • Organoids Master Class Series: Introduction To & Getting Started With Organoids Recorded: Jun 3 2020 60 mins
    Hilary Sherman
    Organoids are radically changing basic research and medicine. These 3D, organ-like collections of cells create innovative approaches to drug development. But how do you get started? That's the subject of our next Organoids Master Class. Our in-house organoids expert will introduce you to organoid technology, explore organoid applications, and reveal culture tips and tricks that will put you on the path to organoid mastery.

    About the Presenter:
    Hilary Sherman is a Senior Scientist in the Corning Life Sciences Applications Lab located in Kennebunk, ME. Hilary has been with Corning Incorporated since 2005 and has worked with a wide variety of cell types including mammalian, insect, primary, stem cells and organoids in a vast array of applications. Her key roles at Corning involve creating technical documents such as protocols and whitepapers as well as providing technical support and training for both the Corning sales force and customers. Hilary received her B.S. degree in Biology from the University of New Hampshire. In the last several years, Hilary has focused on 3D cell culture applications including human organoid culture
Training for Life Science Researchers
The Corning Scientific Seminar Series is a series of free, online technical presentations that provide novel tips, best practices and proven techniques to help advance your research. Delivered by scientists to scientists, these one-hour broadcasts offer useful information and tips for lab technicians and researchers.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Qualidade e Acreditação em Laboratórios-Uma Abordagem da Influência da Vidraria
  • Live at: Jun 2 2020 5:00 pm
  • Presented by: Jeronimo Figueiredo
  • From:
Your email has been sent.
or close